Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

Conditions

• Hematologic Malignancies
• Hematologic Neoplasms

Interventions

• BIOLOGICAL: mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL)
• DRUG: Fludarabine
• DRUG: Cyclophosphamide
• DRUG: Mycophenolate Mofetil
• DRUG: Sirolimus
• DEVICE: CD19 Flow Cytometry Assay
• DEVICE: CD19 Immunohistochemical Assay
• RADIATION: Total Body Irradiation

Sponsor

National Cancer Institute (NCI)